Physician profile
Richard E Miller
NPI 1053533406
$10,430.94
in general payments reported to CMS, 2019-2025
30 companies · $949 in 2025
The $949 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $274 · 2021: $605 · 2022: $937 · 2023: $923 · 2024: $6,077 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,385 · Food and Beverage: $3,438 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,385.17 |
| Food and Beverage | $3,437.62 |
| Education | $127.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $3,000.22 | 2024 | |
| Merck Sharp & Dohme LLC | $1,903.50 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,136.35 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $820.91 | 2021-2025 | |
| Akebia Therapeutics INC | $634.52 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $389.15 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $339.73 | 2019-2024 | Velphoro, Korsuva |
| Vifor Pharma, INC. | $336.62 | 2019-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $278.76 | 2021-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $220.89 | 2020-2025 | Jynarque |
| Amgen INC. | $214.54 | 2019-2025 | Tavneos |
| Mallinckrodt Hospital Products INC. | $189.83 | 2020-2025 | Acthar |
| Calliditas Therapeutics US INC. | $138.19 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $119.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.96 | 2024-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $113.27 | 2022-2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $70.05 | 2025 | |
| Eisai INC. | $55.79 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.68 | 2025 | |
| Travere Therapeutics, INC. | $48.83 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $47.87 | 2019 | |
| Ardelyx, INC. | $46.38 | 2025 | Ibsrela |
| Lilly USA, LLC | $46.23 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $38.34 | 2022-2023 | Benlysta |
| Averitas Pharma INC. | $28.28 | 2025 | Qutenza |
| Daiichi Sankyo INC. | $17.76 | 2021 | |
| Novo Nordisk INC | $16.85 | 2025 | Ozempic |
| Hikma Pharmaceuticals USA | $13.04 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.